Loading
companiesCompany
Taiho Pharmaceutical (Otsuka)
Japanese oncology company behind futibatinib (Lytgobi) for bile duct cancer and the chemotherapy Lonsurf; acquired the ADC linker company Araris in 2025.
Overview
Taiho Pharmaceutical, the Tokyo-based oncology arm of Otsuka, is the company behind futibatinib, sold as Lytgobi, for bile duct cancer, and the chemotherapy Lonsurf, and in 2025 it acquired the antibody-drug conjugate linker company Araris Biotech. Futibatinib was approved in 2022 on the FOENIX-CCA2 trial for FGFR2-altered cholangiocarcinoma, Lonsurf, or trifluridine and tipiracil, is used in colorectal and gastric cancer with TAS-102 combinations under study, and OnCo also links Taiho to S-1, the tegafur, gimeracil and oteracil combination used in Asia. The Araris purchase signals a move from small molecules into ADCs. Whether a chemotherapy-rooted company can build a competitive ADC pipeline from an acquired linker platform is the open question. Futibatinib and Araris have their own pages.
Headquarters
Tokyo, JP
Scorecard
All companies#122of 1244 companies, score 45
- approved products +12
- targets +2
- modalities +4
- regions +4
- registry trials +23
2 approved, 0 in phase 3, 0 earlier, 1 targets, 136 registry studies. Formula on the scorecards page.
Deals
Deal map| Date | Deal | Type | Upfront | Total | Source |
|---|---|---|---|---|---|
| 2025-03 | Araris Biotech (Taiho) to Taiho Pharmaceutical (Otsuka) AraLinQ site-specific ADC linker platform and preclinical ADCs | Acquisition | $400m | up to $1.14bn | source |
Type
Website
ApprovedSmall-molecule irreversible kinase inhibitor (FGFR1-4)
Futibatinib · Lytgobi
Futibatinib is a covalent FGFR inhibitor for FGFR2-fusion bile duct cancer, with the highest response rate of the first-generation drugs.
ApprovedOral fluoropyrimidine combination (antimetabolite)
Tegafur, gimeracil and oteracil (S-1) · Teysuno
Teysuno (S-1) is an oral chemotherapy combining a fluorouracil pro-drug with two protectors. It is a standard in Japan and approved in Europe for stomach cancer with cisplatin and for bowel cancer when other fluoropyrimidines cause hand-foot syndrome or heart problems.
rctNew England Journal of Medicine 2023changed practice374 citations
Trifluridine-tipiracil and bevacizumab in refractory metastatic colorectal cancer (SUNLIGHT)
Trifluridine-tipiracil with bevacizumab is the refractory-line standard, and a reminder that combining two drugs already on the shelf can beat anything new in the same line.
rctNew England Journal of Medicine 2015changed practice1,090 citations
Randomized trial of TAS-102 for refractory metastatic colorectal cancer (RECOURSE)
Trifluridine-tipiracil became the other refractory-line standard alongside regorafenib, and the backbone that SUNLIGHT later improved on by adding bevacizumab.
Similar pages
- TrialFutibatinib (TAS-120) in Patients With Advanced Biliary Tract Cancer
Shares Araris Biotech (Taiho), Futibatinib, Biliary tract cancer (cholangiocarcinoma).
- TrialSUNLIGHT
Shares RECOURSE, Trifluridine-tipiracil and bevacizumab in refractory metastatic colorectal cancer (SUNLIGHT), Colorectal cancer.
- TrialPhase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors
Shares Araris Biotech (Taiho), Futibatinib.
- TrialStudy of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement
Shares Araris Biotech (Taiho), Biliary tract cancer (cholangiocarcinoma).
- PersonLipika Goyal
Shares FOENIX-CCA2, Biliary tract cancer (cholangiocarcinoma).
- TrialA Study Comparing Treatment Preference Between Oral Decitabine/Cedazuridine and Azacitidine in Myelodysplastic Syndrome, Low-Blast Acute Myeloid Leukemia, or Chronic Myelomonocytic Leukemia
Shares Otsuka Pharmaceutical, Myelodysplastic syndromes / neoplasms (MDS).
- PersonJosep Tabernero
Shares Randomized trial of TAS-102 for refractory metastatic colorectal cancer (RECOURSE), Trifluridine-tipiracil and bevacizumab in refractory metastatic colorectal cancer (SUNLIGHT), Colorectal cancer.
- TrialA Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
Shares Araris Biotech (Taiho), Myelodysplastic syndromes / neoplasms (MDS).
cancers
fronts
drugs
ApprovedSmall-molecule irreversible kinase inhibitor (FGFR1-4)
Futibatinib · Lytgobi
ApprovedOral fluoropyrimidine combination (antimetabolite)
Tegafur, gimeracil and oteracil (S-1) · Teysuno